BioNTech SE - ADR vs Stitch Fix Inc — how do they compare? BioNTech SE - ADR trades at $90.53 (market cap $23.31B), while Stitch Fix Inc trades at $3.79 (market cap $530.37M). The key difference: BioNTech SE - ADR is far larger — about 44× Stitch Fix Inc's market cap. Which is the better fit depends on your goals.
| BNTX | SFIX | |
|---|---|---|
Market Cap | $23.31B | $530.37M |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $5.83 |
52-Week Low | $83.89 | $3.06 |
Enterprise Value | $6.60B | $418.08M |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
Stitch Fix (SFIX) trades at $4.20, up 4.22% today, showing stabilization after a multi-year decline. The stock is technically bullish with strong moving average signals, while fundamentals reflect a turnaround with revenue stabilizing at $1.27B and net losses narrowing to -$28.74M in 2025. Recent news highlights AI-driven personalization gains and a debt-free balance sheet, supporting a potential recovery narrative.
The outlook hinges on execution of the turnaround; improving client growth and cost controls offer upside, but persistent losses and consumer spending pressures pose risks. Analysts are cautious with a $4.75 price target and 63.6% hold rating, suggesting the stock may be fairly valued amid its recovery phase.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →